[Efficacy evaluation of epsiprantel (Cestex) against Echinococcus mutilocularis in dogs and cats].
Helminth-free dogs and cats were experimentally infected with protoscoleces of Echinococcus multilocularis and used in controlled trials for efficacy evaluation of the cestodicide epsiprantel. In two separate trials each 4 dogs were treated at day 20 post infection (p.i.) with average oral dosages of 5.1 (4.9-5.3) and 5.4 (5.2-5.8) mg/kg body weight (b.w.) epsiprantel, respectively, and necropsied at day 24 p.i. Among each 4 dogs of the two untreated control groups all animals were infected and had high intestinal worm burdens with averages of 33.575 and 100.725 E. multilocularis specimens per animal (individual worm burdens in group Ib 59,500-149,800, group IIb 20,500-43,200); in the two groups of treated dogs the average worm burdens were reduced by 99.6 and 99.9%. Among 8 treated dogs 4 were helminth-free, the other 4 had residual worm burdens (10-70 in 3 dogs, 1480 in 1 dog). In each 5 cats single oral treatments with average doses of 2.7 (2.7-2.8) and 5.5 (5.5-5.5) mg/kg b.w. epsiprantel were 100% effective against E. multilocularis 20 days p.i. and eliminated the worm burdens from all 10 animals. In the untreated group of 5 cats the average worm burden was 2864 per animal (individual worm burdens 20-6830). Side effects of the drug treatment were not observed. The results of the study show that in single therapeutic dosages recommended by the producer (dogs 5.5 mg, cats 2.75 mg/kg b.w.) epsiprantel eliminates E. multilocularis to over 99% or completely, but residual worm burdens may persist in some animals.
Eckert
J
J
Institut für Parasitologie, Universität Zürich. eje@isi.ch
Thompson
R C
RC
Bucklar
H
H
Bilger
B
B
Deplazes
P
P
D000818:Animals; D000923:Anticestodal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002371:Cat Diseases / Q000188:drug therapy* / Q000469:parasitology; D002415:Cats; D004283:Dog Diseases / Q000188:drug therapy* / Q000469:parasitology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004443:Echinococcosis / Q000188:drug therapy / Q000469:parasitology / Q000662:veterinary*; D004446:Echinococcus / Q000187:drug effects*; D011223:Praziquantel / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
D000923:Anticestodal Agents; C060885:epsiprantel; D011223:Praziquantel